SINGAPORE: Parkway Trust Management Limited, as manager  of  Parkway  Life  Real  Estate  Investment  Trust  (PLife  REIT),  announced that PLife REIT will be included in the FTSE EPRA NAREIT Global Developed Index after the close of business on 18 September 2020.

Yong  Yean  Chau,  Chief  Executive  Officer  of  the Manager,  said:  “It  is  a  significant milestone for us to be included in the index. This bears testament towards our commitment in  achieving  long-term  growth  and  value  for  our  unitholders,  and  highlights  PLife  REIT’s resilience despite on-going uncertainties in the macro economy. Inclusion in the index will enhance trading liquidity and visibility to investors and index funds worldwide, reaffirming our strong position as one of the largest listed healthcare REITs in Asia.”

The  FTSE  EPRA  NAREIT  Global  Developed  Index  incorporates  Real  Estate  Investment Trusts (REITs) and Real Estate Holding & Development companies, and is developed by FTSE Russell in collaboration with the European Public Real Estate Association (EPRA), the European  association  for  listed  real  estate,  as  well  as  the  National  Association  of  Real Estate Investment Trusts (NAREIT), a U.S.-based association for REITs and publicly-traded real estate companies.

The index is designed to track the performance of listed real estate companies and REITS worldwide.

Parkway  Life  Real  Estate  Investment  Trust  (“PLife  REIT”)  is  one  of  Asia’s  largest  listed healthcare REITs by asset size. It invests in income-producing real estate and real estate related  assets  that  are  used  primarily  for  healthcare  and  healthcare-related  purposes (including but are not limited to, hospitals, healthcare facilities and real estate and/or real estate assets used in connection with healthcare research, education, and the manufacture or storage of drugs, medicine and other healthcare goods and devices).

PLife  REIT  owns  a  well-diversified  portfolio  of  53 properties  with  a  total  portfolio  size  of approximately  S$1.96  billion  as  at  30  June  2020. 

It  owns  the  largest  portfolio of strategically-located  private  hospitals  in  Singapore  comprising  Mount  Elizabeth  Hospital, Gleneagles  Hospital  and  Parkway  East  Hospital.  In  addition,  it  has  49  assets  located  in Japan, including one pharmaceutical product distributing and manufacturing facility in Chiba Prefecture  as  well  as  48  high quality  nursing  home and  care facility  properties  in  various prefectures  of  Japan.  It  also  owns  strata-titled  units/lots  in  MOB  Specialist  Clinics  Kuala Lumpur in Malaysia.